Mouse Tnf ASO is an antisense oligonucleotide ( ASO ) that targets the expression of mouse TNF-α. Mouse Tnf ASO reduces the tissue levels of various pro-inflammatory cytokines, Th1 cytokines and Th17 cytokines. Mouse Tnf ASO improves the clinical and histopathological severity of experimental colitis, including alleviating weight loss, diarrhea and intestinal protein loss. Mouse Tnf ASO can be delivered to activated colonic macrophages in mice via galactosylated low-molecular-weight chitosan nanocomplexes, with higher delivery efficiency compared to naked ASO. Mouse Tnf ASO can be used in the research of Crohn's disease [1].
In Vivo, The gal-LMWC/Mouse Tnf ASO complex (0.2-20 mg/kg; i.c.; single administration) reduces colonic TNF-α levels by >85%, eliminates disease symptoms, and achieves 100% survival in mice with TNBS-induced acute colitis[1]. The gal-LMWC/Mouse Tnf ASO complex (5 mg/kg; i.c.; weekly; 5 doses) reduces colonic TNF-α levels by >75% and ameliorates disease symptoms in mice with CD4+CD45RBhi T cell-mediated chronic colitis[1].
In Vitro, Mouse Tnf ASO can be delivered into mouse peritoneal macrophages via the gal-LMWC/ASO complex (incubated for 1 h), with higher efficiency than naked Mouse Tnf ASO; through an MGL-mediated mechanism, the uptake level of this complex is enhanced in LPS-prestimulated activated macrophages[1].
References:
[1]. Zuo L, et al. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut. 2010 Apr;59(4):470-9.
In Vivo, The gal-LMWC/Mouse Tnf ASO complex (0.2-20 mg/kg; i.c.; single administration) reduces colonic TNF-α levels by >85%, eliminates disease symptoms, and achieves 100% survival in mice with TNBS-induced acute colitis[1]. The gal-LMWC/Mouse Tnf ASO complex (5 mg/kg; i.c.; weekly; 5 doses) reduces colonic TNF-α levels by >75% and ameliorates disease symptoms in mice with CD4+CD45RBhi T cell-mediated chronic colitis[1].
In Vitro, Mouse Tnf ASO can be delivered into mouse peritoneal macrophages via the gal-LMWC/ASO complex (incubated for 1 h), with higher efficiency than naked Mouse Tnf ASO; through an MGL-mediated mechanism, the uptake level of this complex is enhanced in LPS-prestimulated activated macrophages[1].
References:
[1]. Zuo L, et al. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut. 2010 Apr;59(4):470-9.